To address this, we used the OGT inhibitor, OSMI-1, and the OGA inhibitor, Thiamet-G (TMG), in HT1080 fibrosarcoma cells harboring WT p53 (HT1080 WT) and compared their response to CRISPR-engineered HT1080 cells in which p53 expression was absent (HT1080 p53KO). Here, OGT is linked to fibrosarcoma.